{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:53:56Z","timestamp":1786114436604,"version":"build-2736575974"},"reference-count":255,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373193"],"award-info":[{"award-number":["82373193"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172649"],"award-info":[{"award-number":["82172649"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2024NSFSC0627"],"award-info":[{"award-number":["2024NSFSC0627"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.apsb.2026.03.047","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:02:07Z","timestamp":1774972927000},"page":"4196-4232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drugging non-canonical kinases in cancer therapeutics: Molecular targets, underlying mechanisms and small-molecule inhibitors"],"prefix":"10.1016","volume":"16","author":[{"given":"Xuelan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongbo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3900-9486","authenticated-orcid":false,"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2026.03.047_bib1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tips.2015.04.005","article-title":"FDA-approved small-molecule kinase inhibitors","volume":"36","author":"Wu","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.apsb.2026.03.047_bib2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2026.03.047_bib3","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.03.047_bib4","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.tips.2019.09.002","article-title":"The landscape of atypical and eukaryotic protein kinases","volume":"40","author":"Kanev","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.apsb.2026.03.047_bib5","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/s41401-020-00577-1","article-title":"Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer","volume":"42","author":"Liang","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2026.03.047_bib6","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1038\/s41388-022-02482-9","article-title":"AKT-mTORC1 reactivation is the dominant resistance driver for PI3K\u03b2\/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors","volume":"41","author":"Dunn","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2026.03.047_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.131064","article-title":"Structure-based investigation of pyruvate dehydrogenase kinase-3 inhibitory potential of thymoquinone, targeting lung cancer therapy","volume":"265","author":"Alotaibi","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2026.03.047_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2026.03.047_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.tibs.2010.09.006","article-title":"Protein kinases: evolution of dynamic regulatory proteins","volume":"36","author":"Taylor","year":"2011","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.apsb.2026.03.047_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1478-811X-9-23","article-title":"The secret life of kinases: functions beyond catalysis","volume":"9","author":"Rauch","year":"2011","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.apsb.2026.03.047_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo2039","article-title":"Structural basis for the calmodulin-mediated activation of eukaryotic elongation factor 2 kinase","volume":"8","author":"Piserchio","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2026.03.047_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.790172","article-title":"Fam20C in human diseases: emerging biological functions and therapeutic implications","volume":"8","author":"Xu","year":"2021","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.apsb.2026.03.047_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189100","article-title":"A role for RIO kinases in the crosshair of cancer research and therapy","volume":"1879","author":"Ghandadi","year":"2024","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.apsb.2026.03.047_bib14","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41589-022-01168-3","article-title":"Small-molecule inhibition of the archetypal UbiB protein COQ8","volume":"19","author":"Murray","year":"2023","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2026.03.047_bib15","article-title":"Pyruvate dehydrogenase kinases (PDKs): an overview toward clinical applications","volume":"41","author":"Wang","year":"2021","journal-title":"Biosci Rep"},{"key":"10.1016\/j.apsb.2026.03.047_bib16","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/febs.17283","article-title":"Atypical MAPKs in cancer","volume":"292","author":"Dahm","year":"2025","journal-title":"FEBS J"},{"key":"10.1016\/j.apsb.2026.03.047_bib17","doi-asserted-by":"crossref","first-page":"16199","DOI":"10.1074\/jbc.273.26.16199","article-title":"The putative cofactor TIF1alpha is a protein kinase that is hyperphosphorylated upon interaction with liganded nuclear receptors","volume":"273","author":"Fraser","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib18","article-title":"TRIM24 cooperates with Ras mutation to drive glioma progression through snoRNA recruitment of PHAX and DNA-PKcs","volume":"11","author":"Xu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2026.03.047_bib19","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1021\/acs.jmedchem.5b00405","article-title":"Structure-guided design of IACS-9571, a selective high-affinity dual TRIM24-BRPF1 bromodomain inhibitor","volume":"59","author":"Palmer","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib20","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/nature09542","article-title":"TRIM24 links a non-canonical histone signature to breast cancer","volume":"468","author":"Tsai","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.047_bib21","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1038\/s41467-022-31735-0","article-title":"TRIM24 is an insulin-responsive regulator of P-bodies","volume":"13","author":"Wei","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.047_bib22","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","article-title":"Histone recognition and large-scale structural analysis of the human bromodomain family","volume":"149","author":"Filippakopoulos","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.03.047_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13578-024-01289-3","article-title":"The tripartite motif-containing 24 is a multifunctional player in human cancer","volume":"14","author":"Yao","year":"2024","journal-title":"Cell Biosci"},{"key":"10.1016\/j.apsb.2026.03.047_bib24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0092-8674(02)00741-9","article-title":"The conformational plasticity of protein kinases","volume":"109","author":"Huse","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.03.047_bib25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41467-021-27944-8","article-title":"HIF-1 interacts with TRIM28 and DNA-PK to release paused RNA polymerase II and activate target gene transcription in response to hypoxia","volume":"13","author":"Yang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.047_bib26","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","article-title":"Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2026.03.047_bib27","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1038\/s41467-023-39657-1","article-title":"Targeted protein degradation reveals BET bromodomains as the cellular target of Hedgehog pathway inhibitor-1","volume":"14","author":"Bagka","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.047_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.101326","article-title":"The intrinsic kinase activity of BRD4 spans its BD2-B-BID domains","volume":"297","author":"Weissman","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib29","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1093\/nar\/gku449","article-title":"Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation","volume":"42","author":"Itzen","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib31","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.3390\/ijms25094725","article-title":"Gaining insights into key structural hotspots within the allosteric binding pockets of protein kinases","volume":"25","author":"Bhujbal","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.03.047_bib32","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BST20220940","article-title":"Allosteric regulation and inhibition of protein kinases","volume":"51","author":"Mingione","year":"2023","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.apsb.2026.03.047_bib33","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.scib.2025.05.009","article-title":"Molecular architecture and inhibition mechanism of human ATR-ATRIP","volume":"70","author":"Wang","year":"2025","journal-title":"Sci Bull"},{"key":"10.1016\/j.apsb.2026.03.047_bib34","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41586-025-09545-3","article-title":"Structural basis for mTORC1 activation on the lysosomal membrane","volume":"647","author":"Cui","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.047_bib35","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.240260","article-title":"Discovery and functional analysis of a novel ALPK1 variant in ROSAH syndrome","volume":"14","author":"Snelling","year":"2024","journal-title":"Open Biol"},{"key":"10.1016\/j.apsb.2026.03.047_bib36","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1021\/acs.jcim.4c00530","article-title":"Identification of potent ADCK3 inhibitors through structure-based virtual screening","volume":"64","author":"Gao","year":"2024","journal-title":"J Chem Inf Model"},{"key":"10.1016\/j.apsb.2026.03.047_bib37","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109432118","article-title":"LRRC8A reduces intracellular chloride to permit WNK activation in response to hypertonic stress","volume":"118","author":"Goldsmith","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.047_bib38","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1038\/s41467-023-38362-3","article-title":"Structural mechanisms of TRPM7 activation and inhibition","volume":"14","author":"Nadezhdin","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.047_bib39","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41467-021-27944-8","article-title":"HIF-1 interacts with TRIM28 and DNA-PK to release paused RNA polymerase II and activate target gene transcription in response to hypoxia","volume":"13","author":"Yang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.047_bib40","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.42426","article-title":"TRIM28 promotes HIV-1 latency by SUMOylating CDK9 and inhibiting P-TEFb","volume":"8","author":"Ma","year":"2019","journal-title":"eLife"},{"key":"10.1016\/j.apsb.2026.03.047_bib41","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.dnarep.2009.04.006","article-title":"Common mechanisms of PIKK regulation","volume":"8","author":"Lovejoy","year":"2009","journal-title":"DNA Repair"},{"key":"10.1016\/j.apsb.2026.03.047_bib42","doi-asserted-by":"crossref","first-page":"8212","DOI":"10.1073\/pnas.1101544108","article-title":"Transcription cofactors TRIM24, TRIM28, and TRIM33 associate to form regulatory complexes that suppress murine hepatocellular carcinoma","volume":"108","author":"Herquel","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.047_bib43","doi-asserted-by":"crossref","first-page":"10941","DOI":"10.1093\/nar\/gkx772","article-title":"The FASTK family of proteins: emerging regulators of mitochondrial RNA biology","volume":"45","author":"Jourdain","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib44","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1074\/jbc.M308820200","article-title":"Characterization of the protein kinase activity of TRPM7\/ChaK1, a protein kinase fused to the transient receptor potential ion channel","volume":"279","author":"Ryazanova","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib45","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/nar\/gkx1236","article-title":"Insights into the evolutionary conserved regulation of Rio ATPase activity","volume":"46","author":"Kn\u00fcppel","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2026.03.047_bib47","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fmolb.2019.00061","article-title":"Beyond the trinity of ATM, ATR, and DNA-PK: multiple kinases shape the DNA damage response in concert with RNA metabolism","volume":"6","author":"Burger","year":"2019","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.apsb.2026.03.047_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2023.102651","article-title":"Structure and function of the apical PIKKs in double-strand break repair","volume":"82","author":"Xu","year":"2023","journal-title":"Curr Opin Struct Biol"},{"key":"10.1016\/j.apsb.2026.03.047_bib49","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13578-020-0376-x","article-title":"ATM, ATR and DNA-PKcs kinases-the lessons from the mouse models: inhibition \u2260 deletion","volume":"10","author":"Menolfi","year":"2020","journal-title":"Cell Biosci"},{"key":"10.1016\/j.apsb.2026.03.047_bib50","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/1878-0261.13343","article-title":"SMG1, a nonsense-mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma","volume":"17","author":"Leeksma","year":"2023","journal-title":"Mol Oncol"},{"key":"10.1016\/j.apsb.2026.03.047_bib51","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16942-w","article-title":"Conservation of nonsense-mediated mRNA decay complex components throughout eukaryotic evolution","volume":"7","author":"Causier","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.03.047_bib52","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/embr.201338080","article-title":"Polo-like kinase-1 triggers histone phosphorylation by Haspin in mitosis","volume":"15","author":"Zhou","year":"2014","journal-title":"EMBO Rep"},{"key":"10.1016\/j.apsb.2026.03.047_bib53","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/embr.201438472","article-title":"Plk1 puts a (has)pin on the mitotic histone code","volume":"15","author":"Moutinho-Santos","year":"2014","journal-title":"EMBO Rep"},{"key":"10.1016\/j.apsb.2026.03.047_bib54","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1126\/science.1189435","article-title":"Histone H3 Thr-3 phosphorylation by Haspin positions Aurora B at centromeres in mitosis","volume":"330","author":"Wang","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.03.047_bib55","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.259546","article-title":"Haspin participates in AURKB recruitment to centromeres and contributes to chromosome congression in male mouse meiosis","volume":"135","author":"Berenguer","year":"2022","journal-title":"J Cell Sci"},{"key":"10.1016\/j.apsb.2026.03.047_bib56","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jgr.2021.11.004","article-title":"Ginsenoside Rg1 suppresses cancer cell proliferation through perturbing mitotic progression","volume":"46","author":"Hong","year":"2022","journal-title":"J Ginseng Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib57","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1021\/acscentsci.3c00332","article-title":"In silico discovery of 5\u2032-modified 7-deoxy-7-ethynyl-4\u2032-thioadenosine as a HASPIN inhibitor and its synergistic anticancer effect with the PLK1 inhibitor","volume":"9","author":"Kwon","year":"2023","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.apsb.2026.03.047_bib58","doi-asserted-by":"crossref","first-page":"4312","DOI":"10.1038\/s41388-020-1296-2","article-title":"Genome-wide CRISPR screen uncovers a synergistic effect of combining Haspin and Aurora kinase B inhibition","volume":"39","author":"Huang","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2026.03.047_bib59","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1097-2765(00)80300-7","article-title":"The ATM-related cofactor Tra1 is a component of the purified SAGA complex","volume":"2","author":"Grant","year":"1998","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2026.03.047_bib60","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/ng725","article-title":"Disruption of Trrap causes early embryonic lethality and defects in cell cycle progression","volume":"29","author":"Herceg","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2026.03.047_bib61","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1042\/BST20180496","article-title":"New insights into the evolutionary conservation of the sole PIKK pseudokinase Tra1\/TRRAP","volume":"47","author":"El\u00edas-Villalobos","year":"2019","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.apsb.2026.03.047_bib62","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/s41467-017-01564-7","article-title":"Structure of the transcription activator target Tra1 within the chromatin modifying complex SAGA","volume":"8","author":"Sharov","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.047_bib63","article-title":"TRIM28 in cancer and cancer therapy","volume":"15","author":"Li","year":"2024","journal-title":"Front Genet"},{"key":"10.1016\/j.apsb.2026.03.047_bib64","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s42003-021-01683-4","article-title":"Crystal structure of the human PRPK\u2013TPRKB complex","volume":"4","author":"Li","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.apsb.2026.03.047_bib65","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.03.047_bib66","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/humu.24472","article-title":"Functional characterization of a novel TP53RK mutation identified in a family with Galloway\u2013Mowat syndrome","volume":"43","author":"Treimer","year":"2022","journal-title":"Hum Mutat"},{"key":"10.1016\/j.apsb.2026.03.047_bib67","doi-asserted-by":"crossref","first-page":"LB-115","DOI":"10.1158\/1538-7445.AM2017-LB-115","article-title":"Abstract LB-115: TPRKB dependency in p53-deficient cancers","volume":"77","author":"VanDenBerg","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib68","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1152\/physrev.00026.2020","article-title":"Regulation and metabolic functions of mTORC1 and mTORC2","volume":"101","author":"Szwed","year":"2021","journal-title":"Physiol Rev"},{"key":"10.1016\/j.apsb.2026.03.047_bib69","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.3390\/ijms25116141","article-title":"mTOR: its critical role in metabolic diseases, cancer, and the aging process","volume":"25","author":"Marafie","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.03.047_bib70","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.3390\/cells8121584","article-title":"Targeting mTOR and metabolism in cancer: lessons and innovations","volume":"8","author":"Magaway","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.apsb.2026.03.047_bib71","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S1097-2765(04)00123-6","article-title":"Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression","volume":"13","author":"Li","year":"2004","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2026.03.047_bib72","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41594-023-01026-3","article-title":"Hierarchical TAF1-dependent co-translational assembly of the basal transcription factor TFIID","volume":"30","author":"Bernardini","year":"2023","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.apsb.2026.03.047_bib73","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/1541-7786.MCR-23-0502","article-title":"AMPK associates with chromatin and phosphorylates the TAF-1 subunit of the transcription initiation complex to regulate histone gene expression in ALL cells","volume":"21","author":"Sun","year":"2023","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib74","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.bbapap.2005.07.037","article-title":"The RIO kinases: an atypical protein kinase family required for ribosome biogenesis and cell cycle progression","volume":"1754","author":"LaRonde-LeBlanc","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2026.03.047_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009583","article-title":"RIOK2 phosphorylation by RSK promotes synthesis of the human small ribosomal subunit","volume":"17","author":"Cerezo","year":"2021","journal-title":"PLoS Genet"},{"key":"10.1016\/j.apsb.2026.03.047_bib76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40169-014-0045-y","article-title":"MELK-a conserved kinase: functions, signaling, cancer, and controversy","volume":"4","author":"Ganguly","year":"2015","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.apsb.2026.03.047_bib77","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noac079.383","article-title":"Inhibition of different mitotic targets demonstrated distinct DNA damage and cell death response in p53-mutant medulloblastoma","volume":"24","author":"Huang","year":"2022","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.apsb.2026.03.047_bib78","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1080\/1061186X.2020.1818760","article-title":"Polo-like kinase 1 as an emerging drug target: structure, function and therapeutic implications","volume":"29","author":"Shakeel","year":"2021","journal-title":"J Drug Target"},{"key":"10.1016\/j.apsb.2026.03.047_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114747","article-title":"Polo-like kinase 1 (PLK1) signaling in cancer and beyond","volume":"193","author":"Iliaki","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2026.03.047_bib80","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.24179","article-title":"CRISPR\/Cas9 mutagenesis invalidates a putative cancer dependency targeted in on-going clinical trials","volume":"6","author":"Lin","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.apsb.2026.03.047_bib81","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150194","article-title":"MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells","volume":"35","author":"Beke","year":"2015","journal-title":"Biosci Rep"},{"key":"10.1016\/j.apsb.2026.03.047_bib82","first-page":"151","article-title":"Therapeutic potential of the mammalian pyruvate dehydrogenase kinases in the prevention of hyperglycaemia","volume":"2","author":"Sugden","year":"2002","journal-title":"Curr Drug Targets: Immune, Endocr Metab Disord"},{"key":"10.1016\/j.apsb.2026.03.047_bib83","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4093\/dmj.2015.39.3.188","article-title":"Pyruvate dehydrogenase kinases: therapeutic targets for diabetes and cancers","volume":"39","author":"Jeoung","year":"2015","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.apsb.2026.03.047_bib84","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.7150\/ijbs.13325","article-title":"Targeting tumor metabolism for cancer treatment: is pyruvate dehydrogenase kinases (PDKs) a viable anticancer target?.","volume":"11","author":"Zhang","year":"2015","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.apsb.2026.03.047_bib85","doi-asserted-by":"crossref","first-page":"14353","DOI":"10.1523\/JNEUROSCI.1910-15.2015","article-title":"Metabolic connection of inflammatory pain: pivotal role of a pyruvate dehydrogenase kinase-pyruvate dehydrogenase\u2013lactic acid axis","volume":"35","author":"Jha","year":"2015","journal-title":"J Neurosci"},{"key":"10.1016\/j.apsb.2026.03.047_bib86","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s42255-023-00912-w","article-title":"PDK4-dependent hypercatabolism and lactate production of senescent cells promotes cancer malignancy","volume":"5","author":"Dou","year":"2023","journal-title":"Nat Metab"},{"key":"10.1016\/j.apsb.2026.03.047_bib87","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1007\/s12311-024-01671-4","article-title":"Mitochondrial dysfunction due to novel COQ8A variation with poor response to CoQ10 treatment: a comprehensive study and review of literatures","volume":"23","author":"Wang","year":"2024","journal-title":"Cerebellum"},{"key":"10.1016\/j.apsb.2026.03.047_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2024.1378083","article-title":"Clinical follow-up of 2 families with glomerulopathy caused by COQ8B gene variants and literature review","volume":"12","author":"Zhang","year":"2025","journal-title":"Front Pediatr"},{"key":"10.1016\/j.apsb.2026.03.047_bib89","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.molcel.2014.11.002","article-title":"Mitochondrial ADCK3 employs an atypical protein kinase-like fold to enable coenzyme Q biosynthesis","volume":"57","author":"Stefely","year":"2015","journal-title":"Mol Cell"},{"key":"10.1016\/j.apsb.2026.03.047_bib90","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1002\/jcsm.13574","article-title":"Prenatal and progressive coenzyme Q10 administration to mitigate muscle dysfunction in mitochondrial disease","volume":"15","author":"Hern\u00e1ndez-Camacho","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.apsb.2026.03.047_bib91","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.tibs.2023.11.004","article-title":"Revealing eEF-2 kinase: recent structural insights into function","volume":"49","author":"Piserchio","year":"2024","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.apsb.2026.03.047_bib92","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2300902120","article-title":"ADP enhances the allosteric activation of eukaryotic elongation factor 2 kinase by calmodulin","volume":"120","author":"Piserchio","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.047_bib93","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1007\/s00204-024-03865-5","article-title":"Research advances on CaMKs-mediated neurodevelopmental injury","volume":"98","author":"Kong","year":"2024","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.apsb.2026.03.047_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104155","article-title":"Targeting eukaryotic elongation factor 2 kinase (eEF2K) with small-molecule inhibitors for cancer therapy","volume":"29","author":"Wang","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2026.03.047_bib95","doi-asserted-by":"crossref","first-page":"4488","DOI":"10.1016\/j.cell.2022.09.042","article-title":"WNK kinases sense molecular crowding and rescue cell volume via phase separation","volume":"185","author":"Boyd-Shiwarski","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.03.047_bib96","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.232","article-title":"WNK1, a molecular crowding sensor, links phase separation to cellular physiological stress","volume":"4","author":"Lan","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.apsb.2026.03.047_bib97","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/MNH.0000000000000915","article-title":"Regulation of the WNK4\u2013SPAK\u2013NCC pathway by the calcium-sensing receptor","volume":"32","author":"Ch\u00e1vez-Canales","year":"2023","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.apsb.2026.03.047_bib98","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3390\/cells12030464","article-title":"Lateral diffusion of NKCC1 contributes to chloride homeostasis in neurons and is rapidly regulated by the WNK signaling pathway","volume":"12","author":"C\u00f4me","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.apsb.2026.03.047_bib99","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1010975","article-title":"Unanticipated domain requirements for Drosophila Wnk kinase in vivo","volume":"19","author":"Yarikipati","year":"2023","journal-title":"PLoS Genet"},{"key":"10.1016\/j.apsb.2026.03.047_bib100","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1038\/s41467-020-18857-z","article-title":"The ALPK1\/TIFA\/NF-\u03baB axis links a bacterial carcinogen to R-loop-induced replication stress","volume":"11","author":"Bauer","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.047_bib101","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1038\/s41598-020-61972-6","article-title":"Structural analysis of TIFA: insight into TIFA-dependent signal transduction in innate immunity","volume":"10","author":"Nakamura","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.03.047_bib102","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41586-018-0433-3","article-title":"Alpha-kinase 1 is a cytosolic innate immune receptor for bacterial ADP-heptose","volume":"561","author":"Zhou","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.047_bib103","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2318794121","article-title":"TIFAB regulates the TIFA\u2013TRAF6 signaling pathway involved in innate immunity by forming a heterodimer complex with TIFA","volume":"121","author":"Nakamura","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.03.047_bib104","doi-asserted-by":"crossref","first-page":"774","DOI":"10.3390\/cells1040774","article-title":"p53-dependent and -independent nucleolar stress responses","volume":"1","author":"Holmberg Olausson","year":"2012","journal-title":"Cells"},{"key":"10.1016\/j.apsb.2026.03.047_bib105","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41420-023-01704-7","article-title":"The RioK1 network determines p53 activity at multiple levels","volume":"9","author":"Damizia","year":"2023","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.apsb.2026.03.047_bib106","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1261\/rna.078994.121","article-title":"The modifying enzyme Tsr3 establishes the hierarchy of Rio kinase binding in 40S ribosome assembly","volume":"28","author":"Huang","year":"2022","journal-title":"RNA"},{"key":"10.1016\/j.apsb.2026.03.047_bib107","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1182\/blood.2021012629","article-title":"Targeting RIOK2 ATPase activity leads to decreased protein synthesis and cell death in acute myeloid leukemia","volume":"139","author":"Messling","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2026.03.047_bib108","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1128\/JVI.00643-14","article-title":"RIOK3 is an adaptor protein required for IRF3-mediated antiviral type I interferon production","volume":"88","author":"Feng","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2026.03.047_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e10116","article-title":"RIOK3 promotes pancreatic ductal adenocarcinoma cell invasion and metastasis by stabilizing FAK","volume":"8","author":"Xu","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.apsb.2026.03.047_bib110","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1021\/acscentsci.3c00332","article-title":"In silico discovery of 5\u2032-modified 7-deoxy-7-ethynyl-4\u2032-thioadenosine as a HASPIN inhibitor and its synergistic anticancer effect with the PLK1 inhibitor","volume":"9","author":"Kwon","year":"2023","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.apsb.2026.03.047_bib111","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13046-022-02352-y","article-title":"The role of TBK1 in cancer pathogenesis and anticancer immunity","volume":"41","author":"Runde","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib112","doi-asserted-by":"crossref","first-page":"aaa2630","DOI":"10.1126\/science.aaa2630","article-title":"Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation","volume":"347","author":"Liu","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.03.047_bib113","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3390\/ijms26051941","article-title":"TANK-binding kinase 1 in the pathogenesis and treatment of inflammation-related diseases","volume":"26","author":"Hui","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.03.047_bib114","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41392-021-00687-0","article-title":"Pattern recognition receptors in health and diseases","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2026.03.047_bib115","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.047_bib116","article-title":"TBK1 is paradoxical in tumor development: a focus on the pathway mediating IFN-I expression","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.03.047_bib117","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1007\/s00018-007-7179-7","article-title":"Phosphorylation and activation of the atypical kinase p53-related protein kinase (PRPK) by Akt\/PKB","volume":"64","author":"Facchin","year":"2007","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.apsb.2026.03.047_bib118","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-143237","article-title":"BRD4 inhibitors enhance the anti-tumor activity of targeted therapy in chronic lymphocytic leukemia","volume":"136","author":"Sundaram","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2026.03.047_bib119","doi-asserted-by":"crossref","first-page":"21186","DOI":"10.1021\/acs.jmedchem.4c01976","article-title":"Discovery of dual CDK6\/BRD4 inhibitor inducing apoptosis and increasing the sensitivity of ferroptosis in triple-negative breast cancer","volume":"67","author":"Zhang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib120","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1182\/blood.2022019274","article-title":"BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis","volume":"142","author":"Schmitt","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2026.03.047_bib121","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3390\/cancers16050959","article-title":"Anticancer effects of BRD4 inhibitor in epithelial ovarian cancer","volume":"16","author":"Kim","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2026.03.047_bib122","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41586-023-05704-6","article-title":"Targeting TBK1 to overcome resistance to cancer immunotherapy","volume":"615","author":"Sun","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.047_bib123","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3390\/microorganisms11051316","article-title":"A bittersweet kiss of gram-negative bacteria: the role of ADP-heptose in the pathogenesis of infection","volume":"11","author":"Sidor","year":"2023","journal-title":"Microorganisms"},{"key":"10.1016\/j.apsb.2026.03.047_bib124","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2023.2295384","article-title":"Fusobacterium nucleatum promotes inflammatory and anti-apoptotic responses in colorectal cancer cells via ADP-heptose release and ALPK1\/TIFA axis activation","volume":"16","author":"Martin-Gallausiaux","year":"2024","journal-title":"Gut Microbes"},{"key":"10.1016\/j.apsb.2026.03.047_bib125","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41586-025-08938-8","article-title":"Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1","volume":"642","author":"Agarwal","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.03.047_bib126","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1136\/annrheumdis-2022-222629","article-title":"Gain-of-function mutations in ALPK1 cause an NF-\u03baB-mediated autoinflammatory disease: functional assessment, clinical phenotyping and disease course of patients with ROSAH syndrome","volume":"81","author":"Kozycki","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.apsb.2026.03.047_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2020.100754","article-title":"Recurrent copy number gains drive PKC\u03b9 expression and PKC\u03b9-dependent oncogenic signaling in human cancers","volume":"78","author":"Liu","year":"2020","journal-title":"Adv Biol Regul"},{"key":"10.1016\/j.apsb.2026.03.047_bib128","doi-asserted-by":"crossref","DOI":"10.1038\/srep12520","article-title":"PKC\u03b6 promotes breast cancer invasion by regulating expression of E-cadherin and zonula occludens-1 (ZO-1) via NF\u03baB-p65","volume":"5","author":"Paul","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.03.047_bib129","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cellsig.2017.06.016","article-title":"Downregulation of PKC\u03b6\/Pard3\/Pard6b is responsible for lung adenocarcinoma cell EMT and invasion","volume":"38","author":"Zhou","year":"2017","journal-title":"Cell Signal"},{"key":"10.1016\/j.apsb.2026.03.047_bib130","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.celrep.2019.12.071","article-title":"Chromosome 3q26 cain is an early event driving coordinated overexpression of the PRKCI, SOX2, and ECT2 oncogenes in lung squamous cell carcinoma","volume":"30","author":"Liu","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2026.03.047_bib131","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12935-020-01688-9","article-title":"YAP manipulates proliferation via PTEN\/AKT\/mTOR-mediated autophagy in lung adenocarcinomas","volume":"21","author":"Xu","year":"2021","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.apsb.2026.03.047_bib132","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.canlet.2018.02.015","article-title":"The Hippo\/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer","volume":"423","author":"Lu","year":"2018","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2026.03.047_bib133","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1038\/s41467-024-49230-z","article-title":"A YAP-centered mechanotransduction loop drives collective breast cancer cell invasion","volume":"15","author":"Khalil","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.047_bib134","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1158\/1541-7786.MCR-10-0359","article-title":"Atypical protein kinase C\u03b9 (PKC\u03b9) promotes metastasis of esophageal squamous cell carcinoma by enhancing resistance to Anoikis via PKC\u03b9\u2013SKP2\u2013AKT pathway","volume":"9","author":"Liu","year":"2011","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib135","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1002\/jcp.30759","article-title":"NF-\u03baB as a regulator of cancer metastasis and therapy response: a focus on epithelial-mesenchymal transition","volume":"237","author":"Mirzaei","year":"2022","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.apsb.2026.03.047_bib136","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1158\/1538-7445.AM2022-150","article-title":"Abstract 150: prevalent PKC-\u03b9\/\u03b6 signaling is crucial for apoptosis inhibition and invasiveness of glioblastoma through upregulation of Pdk1\/Akt1\/14-3-3 cascade and Smad2\/3","volume":"82","author":"Ratnayake","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib137","article-title":"FAM20C: a key protein kinase in multiple diseases","volume":"12","author":"Zhang","year":"2025","journal-title":"Genes Dis"},{"key":"10.1016\/j.apsb.2026.03.047_bib138","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20210040","article-title":"From biomineralization to tumorogenesis\u2014the expanding insight of the physiological and pathological roles of Fam20C","volume":"41","author":"Wu","year":"2021","journal-title":"Biosci Rep"},{"key":"10.1016\/j.apsb.2026.03.047_bib139","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1158\/0008-5472.CAN-20-3328","article-title":"Fam20C regulates bone resorption and breast cancer bone metastasis through osteopontin and BMP4","volume":"81","author":"Zuo","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113088","article-title":"Discovery of a novel small-molecule inhibitor of Fam20C that induces apoptosis and inhibits migration in triple negative breast cancer","volume":"210","author":"Zhao","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib141","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.3390\/cancers13246322","article-title":"TRPM7 ion channel: oncogenic roles and therapeutic potential in breast cancer","volume":"13","author":"Cordier","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2026.03.047_bib142","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41416-020-0991-7","article-title":"A novel TRPM7\/O-GlcNAc axis mediates tumour cell motility and metastasis by stabilising c-Myc and caveolin-1 in lung carcinoma","volume":"123","author":"Luanpitpong","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2026.03.047_bib143","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1158\/0008-5472.CAN-11-3863","article-title":"TRPM7 is required for breast tumor cell metastasis","volume":"72","author":"Middelbeek","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib144","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abh3457","article-title":"The fluid shear stress sensor TRPM7 regulates tumor cell intravasation","volume":"7","author":"Yankaskas","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2026.03.047_bib145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.canlet.2021.10.043","article-title":"Stimulating TRPM7 suppresses cancer cell proliferation and metastasis by inhibiting autophagy","volume":"525","author":"Xing","year":"2022","journal-title":"Cancer Lett"},{"key":"10.1016\/j.apsb.2026.03.047_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114108","article-title":"Structural basis of selective TRPM7 inhibition by the anticancer agent CCT128930","volume":"43","author":"Nadezhdin","year":"2024","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2026.03.047_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113142","article-title":"Exploring therapeutic potential: targeting TRPM7 in neurodegenerative diseases","volume":"142","author":"Soni","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.apsb.2026.03.047_bib148","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1021\/acs.jmedchem.5b00458","article-title":"Discovery of a chemical tool inhibitor targeting the bromodomains of TRIM24 and BRPF","volume":"59","author":"Bennett","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib149","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13578-024-01289-3","article-title":"The tripartite motif-containing 24 is a multifunctional player in human cancer","volume":"14","author":"Yao","year":"2024","journal-title":"Cell Biosci"},{"issue":"9","key":"10.1016\/j.apsb.2026.03.047_bib150","doi-asserted-by":"crossref","DOI":"10.1098\/rsos.240790","article-title":"The roles of TAF1 in neuroscience and beyond","volume":"11","author":"Crombie","year":"2024","journal-title":"R Soc Open Sci"},{"key":"10.1016\/j.apsb.2026.03.047_bib151","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.bbrc.2023.04.100","article-title":"Targeting TAF1 with BAY-299 induces antitumor immunity in triple-negative breast cancer","volume":"665","author":"Zhang","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.apsb.2026.03.047_bib152","doi-asserted-by":"crossref","first-page":"9301","DOI":"10.1021\/acs.jmedchem.8b01225","article-title":"GNE-371, a potent and selective chemical probe for the second bromodomains of human transcription-initiation-factor TFIID subunit 1 and transcription-initiation-factor TFIID subunit 1-like","volume":"61","author":"Wang","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib153","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202404645","article-title":"The pseudo-natural product tafbromin selectively targets the TAF1 bromodomain 2","volume":"63","author":"Patil","year":"2024","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2026.03.047_bib154","doi-asserted-by":"crossref","first-page":"7549","DOI":"10.3390\/ijms21207549","article-title":"Cdc-like kinases (CLKs): biology, chemical probes, and therapeutic potential","volume":"21","author":"Mart\u00edn Moyano","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.03.047_bib155","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/med.21928","article-title":"An overview of cdc2-like kinase 1 (Clk1) inhibitors and their therapeutic indications","volume":"43","author":"ElHady","year":"2023","journal-title":"Med Res Rev"},{"key":"10.1016\/j.apsb.2026.03.047_bib156","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12943-024-02043-6","article-title":"Insights into the structural and functional activities of forgotten Kinases: PCTAIREs CDKs","volume":"23","author":"Karimbayli","year":"2024","journal-title":"Mol Cancer"},{"key":"10.1016\/j.apsb.2026.03.047_bib157","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","article-title":"Cyclin-dependent protein kinases and cell cycle regulation in biology and disease","volume":"10","author":"Pellarin","year":"2025","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2026.03.047_bib158","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/s41419-022-05249-y","article-title":"An update regarding the role of WNK kinases in cancer","volume":"13","author":"Xiu","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2026.03.047_bib159","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.drudis.2017.10.005","article-title":"Haspin: a promising target for the design of inhibitors as potent anticancer drugs","volume":"23","author":"Amoussou","year":"2018","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2026.03.047_bib160","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/jpp\/rgac080","article-title":"Function and inhibition of Haspin kinase: targeting multiple cancer therapies by antimitosis","volume":"75","author":"Liu","year":"2023","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.apsb.2026.03.047_bib161","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1039\/C6MB00111D","article-title":"Systematic network-based discovery of a Fam20C inhibitor (FL-1607) with apoptosis modulation in triple-negative breast cancer","volume":"12","author":"Qin","year":"2016","journal-title":"Mol Biosyst"},{"key":"10.1016\/j.apsb.2026.03.047_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.138398","article-title":"Discovery of a novel Fam20C inhibitor for treatment of triple-negative breast cancer","volume":"286","author":"Lu","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.apsb.2026.03.047_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107160","article-title":"Recent advances in pyruvate dehydrogenase kinase inhibitors: structures, inhibitory mechanisms and biological activities","volume":"144","author":"Li","year":"2024","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib164","article-title":"Design and characterization of a novel eEF2K degrader with potent therapeutic efficacy against triple-negative breast cancer","volume":"11","author":"Zhong","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2026.03.047_bib165","doi-asserted-by":"crossref","first-page":"15837","DOI":"10.1021\/acs.jmedchem.4c01484","article-title":"Structure\u2013activity relationship studies of substituted 2-phenyl-1,2,4-triazine-3,5(2H,4H)-dione analogues: development of potent eEF2K degraders against triple-negative breast cancer","volume":"67","author":"Zhao","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117210","article-title":"Identification of a selective pyruvate dehydrogenase kinase 1 (PDHK1) chemical probe by virtual screening","volume":"284","author":"Baber","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib167","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1158\/0008-5472.CAN-15-1023","article-title":"JX06 selectively inhibits pyruvate dehydrogenase kinase PDK1 by a covalent cysteine modification","volume":"75","author":"Sun","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib168","doi-asserted-by":"crossref","first-page":"12862","DOI":"10.18632\/oncotarget.2656","article-title":"VER-246608, a novel pan-isoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells","volume":"5","author":"Moore","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2026.03.047_bib169","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2147\/DDDT.S389461","article-title":"Identification of a class of WNK isoform-specific inhibitors through high-throughput screening","volume":"17","author":"Chlebowicz","year":"2023","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.apsb.2026.03.047_bib170","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/nchembio.2168","article-title":"Small-molecule WNK inhibition regulates cardiovascular and renal function","volume":"12","author":"Yamada","year":"2016","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2026.03.047_bib171","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/aps.2015.123","article-title":"Eukaryotic elongation factor 2 kinase as a drug target in cancer, and in cardiovascular and neurodegenerative diseases","volume":"37","author":"Liu","year":"2016","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2026.03.047_bib172","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41589-018-0010-y","article-title":"Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands","volume":"14","author":"Gechijian","year":"2018","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.apsb.2026.03.047_bib173","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1021\/acs.jmedchem.1c01999","article-title":"Discovery of dual TAF1-ATR inhibitors and ligand-induced structural changes of the TAF1 tandem bromodomain","volume":"65","author":"Karim","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib174","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1158\/1535-7163.MCT-24-1091","article-title":"PROTAC-mediated degradation of TAF1 induces apoptosis in AML cells and inhibits tumor growth in vivo","volume":"24","author":"Chen","year":"2025","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.apsb.2026.03.047_bib175","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1021\/acsmedchemlett.9b00243","article-title":"Dual inhibition of TAF1 and BET bromodomains from the BI-2536 kinase inhibitor scaffold","volume":"10","author":"Remillard","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2026.03.047_bib176","article-title":"Combination CDC-like kinase inhibition (CLK)\/dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1-mutated endometrial cancer","author":"Corr","year":"2023","journal-title":"bioRxiv [Preprint]"},{"key":"10.1016\/j.apsb.2026.03.047_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115962","article-title":"Discovery of DB18, a potent inhibitor of CLK kinases with a high selectivity against DYRK1A kinase","volume":"31","author":"Brahmaiah","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib178","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1021\/acscentsci.3c00332","article-title":"In silico discovery of 5\u2032-modified 7-deoxy-7-ethynyl-4\u2032-thioadenosine as a HASPIN inhibitor and its synergistic anticancer effect with the PLK1 inhibitor","volume":"9","author":"Kwon","year":"2023","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.apsb.2026.03.047_bib179","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1158\/0008-5472.CAN-19-2330","article-title":"Inhibition of Haspin kinase promotes cell-intrinsic and extrinsic antitumor activity","volume":"80","author":"Melms","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib180","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/onc.2011.335","article-title":"Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin","volume":"31","author":"Huertas","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2026.03.047_bib181","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249912","article-title":"Evaluation of the antiproliferative effects of the HASPIN inhibitor CHR-6494 in breast cancer cell lines","volume":"16","author":"Nishida-Fukuda","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2026.03.047_bib182","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1182\/blood-2022-162773","article-title":"The serine\/threonine kinase HASPIN is a novel dependency in t(8;21) AML","volume":"140","author":"Liu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2026.03.047_bib183","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2025.100107","article-title":"Targeting HASPIN kinase disrupts SR protein-mediated RNA splicing and synergizes with BCL-2 inhibitor venetoclax in AML","volume":"2","author":"Liu","year":"2025","journal-title":"Blood Neoplasia"},{"key":"10.1016\/j.apsb.2026.03.047_bib184","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.chembiol.2019.02.015","article-title":"Discovery of covalent CDK14 inhibitors with pan-TAIRE family specificity","volume":"26","author":"Ferguson","year":"2019","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2026.03.047_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111331","article-title":"CDK14 inhibition reduces mammary stem cell activity and suppresses triple negative breast cancer progression","volume":"40","author":"Zhang","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2026.03.047_bib186","doi-asserted-by":"crossref","first-page":"33779","DOI":"10.18632\/oncotarget.16810","article-title":"SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains","volume":"8","author":"Rzymski","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2026.03.047_bib187","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41401-020-00512-4","article-title":"Waixenicin A, a marine-derived TRPM7 inhibitor: a promising CNS drug lead","volume":"41","author":"Sun","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2026.03.047_bib188","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41419-025-07665-2","article-title":"The kinase domain of TRPM7 interacts with PAK1 and regulates pancreatic cancer cell epithelial-to-mesenchymal transition","volume":"16","author":"Auwercx","year":"2025","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.apsb.2026.03.047_bib189","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.1038\/s41467-023-41381-9","article-title":"Pharmacological inhibition of TBK1\/IKK\u03b5 blunts immunopathology in a murine model of SARS-CoV-2 infection","volume":"14","author":"Ullah","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.047_bib190","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1021\/acsmedchemlett.9b00027","article-title":"Discovery of GSK8612, a highly selective and potent TBK1 inhibitor","volume":"10","author":"Thomson","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2026.03.047_bib191","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1158\/2159-8290.CD-19-0837","article-title":"TBK1 is a synthetic lethal target in cancer with VHL loss","volume":"10","author":"Hu","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2026.03.047_bib192","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.3390\/ijms26051941","article-title":"TANK-binding kinase 1 in the pathogenesis and treatment of inflammation-related diseases","volume":"26","author":"Hui","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.03.047_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118137","article-title":"ATM inhibitors in cancer radiotherapy: mechanisms, clinical development, and future directions","volume":"300","author":"Al-Zoubi","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib194","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2025.2489720","article-title":"Medicinal chemistry breakthroughs on ATM, ATR, and DNA-PK inhibitors as prospective cancer therapeutics","volume":"40","author":"Sharma","year":"2025","journal-title":"J Enzym Inhib Med Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib195","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1158\/1535-7163.MCT-21-0934","article-title":"A new class of selective ATM inhibitors as combination partners of DNA double-strand break inducing cancer therapies","volume":"21","author":"Zimmermann","year":"2022","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.apsb.2026.03.047_bib196","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/neuonc\/noaf102","article-title":"The novel brain penetrant ataxia-telangiectasia mutated inhibitor WSD0628 provides robust radiosensitization of brain tumor patient-derived xenografts","volume":"27","author":"Xue","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.apsb.2026.03.047_bib197","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s11523-025-01136-6","article-title":"The development of ATM inhibitors in cancer therapy","volume":"20","author":"Ampolini","year":"2025","journal-title":"Targeted Oncol"},{"key":"10.1016\/j.apsb.2026.03.047_bib198","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005041","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer","volume":"10","author":"Kwon","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.apsb.2026.03.047_bib199","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ygyno.2022.11.014","article-title":"Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma","volume":"168","author":"Harold","year":"2023","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.apsb.2026.03.047_bib200","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/1535-7163.MCT-21-0615","article-title":"RP-3500: a novel, potent, and selective ATR inhibitor that is effective in preclinical models as a monotherapy and incombination with PARP inhibitors","volume":"21","author":"Roulston","year":"2022","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.apsb.2026.03.047_bib201","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1078-0432.CCR-23-2409","article-title":"First-in-human study of the ataxia telangiectasia and Rad3-related (ATR) inhibitor Tuvusertib (M1774) as monotherapy in patients with solid tumors","volume":"30","author":"Yap","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib202","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2026.03.047_bib203","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41416-023-02436-2","article-title":"A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumours","volume":"130","author":"Burris","year":"2024","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2026.03.047_bib204","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1158\/1538-7445.AM2022-2604","article-title":"Abstract 2604: the novel ATR inhibitor ATG-018 is efficacious in preclinical cancer models","volume":"82","author":"Yuwen","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib205","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1158\/1538-7445.AM2025-4203","article-title":"Abstract 4203: discovery and development of a potent and highly selective ATR inhibitor IMP9064","volume":"85","author":"Cai","year":"2025","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib206","doi-asserted-by":"crossref","first-page":"6177","DOI":"10.1158\/1538-7445.AM2023-6177","article-title":"Abstract 6177: ATRN-119 and ATRN-W1051: novel and potentially well tolerated ATR and WEE1 inhibitors for targeted cancer treatment","volume":"83","author":"Vacca","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib207","doi-asserted-by":"crossref","first-page":"12735","DOI":"10.1021\/acs.jmedchem.4c00734","article-title":"Discovery of preclinical candidate AD1058 as a highly potent, selective, and brain-penetrant ATR inhibitor for the treatment of advanced malignancies","volume":"67","author":"Liu","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib208","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41416-025-03053-x","article-title":"The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I\/IIa study","volume":"133","author":"Yap","year":"2025","journal-title":"Br J Cancer"},{"key":"10.1016\/j.apsb.2026.03.047_bib209","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.3390\/ijms25105120","article-title":"Peposertib, a DNA-PK inhibitor, enhances the anti-tumor efficacy of topoisomerase II inhibitors in triple-negative breast cancer models","volume":"25","author":"Revia","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.03.047_bib210","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1158\/1535-7163.MCT-17-1267","article-title":"The DNA-PK inhibitor VX-984 enhances the radiosensitivity of glioblastoma cells grown in vitro and as orthotopic xenografts","volume":"17","author":"Timme","year":"2018","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.apsb.2026.03.047_bib211","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1158\/1535-7163.MCT-23-0890","article-title":"A novel dual ATM\/DNA-PK inhibitor, XRD-0394, potently radiosensitizes and potentiates PARP and topoisomerase I inhibitors","volume":"23","author":"Gilmer","year":"2024","journal-title":"Mol Cancer Therapeut"},{"key":"10.1016\/j.apsb.2026.03.047_bib212","doi-asserted-by":"crossref","first-page":"10463","DOI":"10.2147\/CMAR.S208720","article-title":"First-in-human phase I study of a dual mTOR kinase and DNA-PK inhibitor (CC-115) in advanced malignancy","volume":"11","author":"Munster","year":"2019","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib213","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3125.PI3K-mTOR18-B08","article-title":"Abstract B08: improved tumor penetration, antitumor activity, and survival of ABI-009 (nab-sirolimus) versus oral rapamycin and everolimus and investigation of mTOR pathway inhibition","volume":"18","author":"Schmid","year":"2020","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib214","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.MECHRES-B58","article-title":"Abstract B58: the ATP-competitive mammalian target of rapamycin (mTOR) inhibitors suppress proliferation and induce apoptosis in the acquired rapamycin resistant breast cancer cells","volume":"18","author":"Tzung-Ju","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib215","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nrd3531","article-title":"Rapamycin passes the torch: a new generation of mTOR inhibitors","volume":"10","author":"Benjamin","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.03.047_bib216","article-title":"Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2-deficient models","volume":"6","author":"Bhattacharyya","year":"2024","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.apsb.2026.03.047_bib217","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1038\/s41388-020-1202-y","article-title":"Preclinical evaluation of a novel triple-acting PIM\/PI3K\/mTOR inhibitor, IBL-302, in breast cancer","volume":"39","author":"Kennedy","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2026.03.047_bib218","doi-asserted-by":"crossref","first-page":"15297","DOI":"10.18632\/oncotarget.3812","article-title":"A small molecule inhibitor of atypical protein kinase C signaling inhibits pancreatic cancer cell transformed growth and invasion","volume":"6","author":"Butler","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.apsb.2026.03.047_bib219","doi-asserted-by":"crossref","first-page":"5216","DOI":"10.1158\/1538-7445.AM2020-5216","article-title":"Abstract 5216: atypical PKC inhibitors ICA-1S and \u03b6-Stat show inhibition of neuroblastoma cell proliferation","volume":"80","author":"Breedy","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib220","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw8412","article-title":"Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials","volume":"11","author":"Lin","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2026.03.047_bib221","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.32838","article-title":"MELK expression correlates with tumor mitotic activity but is not required for cancer growth","volume":"7","author":"Giuliano","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.apsb.2026.03.047_bib222","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1038\/s41388-018-0333-x","article-title":"Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia","volume":"37","author":"Zhang","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.apsb.2026.03.047_bib223","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS22-P6-10-08","article-title":"Abstract P6-10-08: evaluation of potent novel second-generation MELK-selective inhibitor in aggressive breast cancers","volume":"83","author":"Mughees","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib224","first-page":"135","article-title":"Roscovitine in cancer and other diseases","volume":"3","author":"Cicenas","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.apsb.2026.03.047_bib225","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/blood.V122.21.871.871","article-title":"Dinaciclib (SCH 727965) is a novel cyclin-dependent kinase (CDK) inhibitor that exhibits activity in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)","volume":"122","author":"Flynn","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2026.03.047_bib226","first-page":"1913","article-title":"CDK inhibitors in cancer therapy, an overview of recent development","volume":"11","author":"Zhang","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib227","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1158\/1538-7445.AM2016-2816","article-title":"Abstract 2816: evaluation of Cdk5 inhibitors in neural crest tumors","volume":"76","author":"Norris","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib228","doi-asserted-by":"crossref","first-page":"13865","DOI":"10.1002\/anie.202004087","article-title":"Development of CDK2 and CDK5 dual degrader TMX-2172","volume":"59","author":"Teng","year":"2020","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.apsb.2026.03.047_bib229","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ejmech.2016.01.011","article-title":"5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases","volume":"110","author":"Vym\u011btalov\u00e1","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib230","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s00894-014-2407-1","article-title":"Structural basis of valmerins as dual inhibitors of GSK3\u03b2\/CDK5","volume":"20","author":"Li","year":"2014","journal-title":"J Mol Model"},{"key":"10.1016\/j.apsb.2026.03.047_bib231","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1126\/science.aae0477","article-title":"Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity","volume":"353","author":"Dorand","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.03.047_bib232","article-title":"CDK5 inhibition abrogates TNBC stem-cell property and enhances anti-PD-1 therapy","volume":"7","author":"Bei","year":"2020","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2026.03.047_bib233","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3390\/cells13050368","article-title":"The CDK inhibitor dinaciclib improves cisplatin response in nonseminomatous testicular cancer: a preclinical study","volume":"13","author":"Rossini","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.apsb.2026.03.047_bib234","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.apsb.2019.07.004","article-title":"Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity","volume":"10","author":"Deng","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.03.047_bib235","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00247-1","article-title":"Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study","volume":"3","author":"Berthon","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.apsb.2026.03.047_bib236","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1158\/1078-0432.CCR-22-1284","article-title":"A phase I\/II open-label study of Molibresib for the treatment of relapsed\/refractory hematologic malignancies","volume":"29","author":"Dawson","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib237","doi-asserted-by":"crossref","first-page":"8369","DOI":"10.1021\/acs.jmedchem.7b00746","article-title":"Discovery of N-(4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075\/Mivebresib), a potent and orally available bromodomain and extraterminal domain (BET) family bromodomain inhibitor","volume":"60","author":"McDaniel","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib238","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1200\/JCO.22.01972","article-title":"MANIFEST: pelabresib in combination with Ruxolitinib for Janus kinase inhibitor treatment-na\u00efve myelofibrosis","volume":"41","author":"Mascarenhas","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2026.03.047_bib239","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","article-title":"Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2026.03.047_bib240","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1021\/acs.jmedchem.0c00628","article-title":"Discovery of N-ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET bromodomain inhibitor with selectivity for the second bromodomain","volume":"63","author":"Sheppard","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2026.03.047_bib241","doi-asserted-by":"crossref","first-page":"6264","DOI":"10.1158\/1538-7445.AM2023-6264","article-title":"Abstract 6264: NUV-868, a novel BD2-selective BET inhibitor, in combination with enzalutamide or olaparib, inhibits growth of solid tumor xenografts","volume":"83","author":"Patel","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib242","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.apsb.2025.01.007","article-title":"Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors","volume":"15","author":"Zhang","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.03.047_bib243","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104499","article-title":"Final results from the phase Ia\/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma","volume":"10","author":"Lauer","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.apsb.2026.03.047_bib244","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1200\/JCO.2021.39.15_suppl.3018","article-title":"Phase 1b\/2a study of PLX2853, a small molecule BET inhibitor, in subjects with advanced solid tumors and lymphoma","volume":"39","author":"Gordon","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2026.03.047_bib245","doi-asserted-by":"crossref","first-page":"7897","DOI":"10.1021\/jacs.4c18398","article-title":"A dual-targeted molecule for disease-activatable proteolysis targeting chimeras and targeted radionuclide therapy of cancer","volume":"147","author":"Zhang","year":"2025","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2026.03.047_bib246","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/s41467-024-46167-1","article-title":"Delivery of a BET protein degrader via a CEACAM6-targeted antibody\u2013drug conjugate inhibits tumour growth in pancreatic cancer models","volume":"15","author":"Nakazawa","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.03.047_bib247","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1158\/1538-7445.AM2024-2461","article-title":"Abstract 2461: discovery of an orally available and liver-targeted ALPK1 agonist for cancer immunotherapy","volume":"84","author":"Wang","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.03.047_bib248","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hep.32614","article-title":"Alpha-kinase 1 (ALPK1) agonist DF-006 demonstrates potent efficacy in mouse and primary human hepatocyte (PHH) models of hepatitis B","volume":"77","author":"Xu","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.apsb.2026.03.047_bib249","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.3390\/cancers13071628","article-title":"Non-canonical kinases and substrates in cancer progression","volume":"13","author":"Vega","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.apsb.2026.03.047_bib250","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103881","article-title":"Illuminating function of the understudied druggable kinome","volume":"29","author":"Gomez","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2026.03.047_bib251","doi-asserted-by":"crossref","first-page":"831","DOI":"10.20892\/j.issn.2095-3941.2024.0327","article-title":"Inflammatory signaling in targeted therapy resistance: focus on EGFR-targeted treatment","volume":"21","author":"Luo","year":"2024","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.apsb.2026.03.047_bib252","article-title":"Opportunities for protein kinase drug discovery\u20142025 update on the chemically underexplored human kinome","volume":"15","author":"Koch","year":"2025","journal-title":"Eur J Med Chem Rep"},{"key":"10.1016\/j.apsb.2026.03.047_bib253","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.16087","article-title":"Dark kinase annotation, mining, and visualization using the Protein Kinase Ontology","volume":"11","author":"Soleymani","year":"2023","journal-title":"PeerJ"},{"key":"10.1016\/j.apsb.2026.03.047_bib254","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s12964-024-01868-4","article-title":"Illuminating the dark kinome: utilizing multiplex peptide activity arrays to functionally annotate understudied kinases","volume":"22","author":"Hamoud","year":"2024","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.apsb.2026.03.047_bib255","doi-asserted-by":"crossref","DOI":"10.1039\/D5MD00306G","article-title":"Identifying and evaluating understudied protein kinases using biological and chemical criteria","author":"Koch","year":"2025","journal-title":"RSC Med Chem"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526002078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526002078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T20:53:39Z","timestamp":1785963219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383526002078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":255,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2211383526002078"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2026.03.047","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drugging non-canonical kinases in cancer therapeutics: Molecular targets, underlying mechanisms and small-molecule inhibitors","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2026.03.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}